Search

Your search keyword '"Patti, F"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Patti, F" Remove constraint Author: "Patti, F" Topic medicine Remove constraint Topic: medicine
106 results on '"Patti, F"'

Search Results

1. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

2. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

3. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

4. Italian consensus on treatment of spasticity in multiple sclerosis

5. Long-term safety and efficacy of Eculizumab in Aquaporin-4 IgG-positive NMOSD

6. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

7. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)

8. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

9. Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

10. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

11. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

12. Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study

13. Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis

14. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group

15. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

16. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

17. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

18. Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2)

19. Genetic burden of common variants in progressive and bout-onset multiple sclerosis

20. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

21. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment

22. Family Support in Early Hearing Detection and Intervention (EHDI) Systems

23. Verification of Speech Spectrum Audibility for Pediatric Baha Softband Users with Craniofacial Anomalies

24. Dimensions of Care Model and Pediatric Audiology

25. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

26. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis

27. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study

28. Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis

29. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

30. Failed newborn hearing screens as presentation for otitis media with effusion in the newborn population

31. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study

32. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis

33. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

34. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis

35. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis

36. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

37. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis - Results of the βPlus observational cohort study

38. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

39. Psychosocial issue in children and adolescents with multiple sclerosis

40. Infant hearing screening

41. Health state preference scores for children with permanent childhood hearing loss: a comparative analysis of the QWB and HUI3

42. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results

43. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study

44. Universal Pediatric Hearing Screening

45. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

46. Listening to the neurological teams for multiple sclerosis: the SMART project

47. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

48. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

49. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

50. Failed newborn hearing screens as presentation for otitis media with effusion in the newborn population

Catalog

Books, media, physical & digital resources